Feng Zhu

Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms

J. Winter, M. Piris, W. Tam, 2021, Blood Cancer Journal.

Effects of fertilization regimes on weed seed banks in a rice–wheat crop system

Guojun Sun, Dongping Xu, Haiyan Zhang, 2016 .

XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53

W. Choi, J. Winter, M. Piris, 2020, Journal of Hematology & Oncology.

EBV+ high‐grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: a multi‐institutional study

Y. Li, K. Young, Z. Xu-Monette, 2021, Histopathology.

A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL.

B. Shahbaba, J. Winter, M. Piris, 2020, Blood Advances.

Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents

J. Winter, M. Piris, W. Tam, 2020, Molecular Cancer Research.

Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia

K. Young, Z. Xu-Monette, R. Orlowski, 2021, Neoplasia.

Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma

J. Winter, M. Piris, G. Bhagat, 2021, Oncoimmunology.

Genetic subtyping and phenotypic characterization of the immune microenvironment and MYC/BCL2 double expression reveal heterogeneity in diffuse large B-cell lymphoma.

J. Winter, M. Piris, W. Tam, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

The synergy of the XPO1 inhibitors combined with the BET inhibitor INCB057643 in high-grade B-cell lymphoma via downregulation of MYC expression

Haijun Zhao, Manman Deng, X. Fang, 2023, Scientific reports.